Development and Reform Commission re-starts drug prices

The National Development and Reform Commission recently issued a notice stating that in order to understand the cost, price, and relevant conditions in the production and distribution of pharmaceuticals, it is timely to formulate price adjustments for pharmaceuticals and decided to conduct cost investigations and factory (port) price surveys on some pharmaceutical companies, among which many listed companies In the column.

According to the “Notice” requirement, the NDRC's Drug Price Evaluation Center will form an investigation team to conduct field investigations from relevant companies during the period from July to the end of October. For the ex-factory price survey, the survey will mainly focus on the 2012 government pricing of pharmaceuticals and the ex-factory prices. The basic conditions of the production company's financial operations, etc.

The list of ex-factory price surveys includes 33 pharmaceutical companies, among which are listed companies such as Shuanglu Pharmaceutical, Jinling Pharmaceutical, All Health Pharmaceutical, and Kunming Pharmaceutical. In addition, Guangzhou Pharmaceutical Group Guangzhou Pharmaceutical and Wuliangye Group Yibin Pharmaceutical and other related companies Also in the column.

For the cost investigation, the “Notice” deployment of the survey was mainly related to the company's 2010-2012 three consecutive years of all drug production, sales, cost and price and other relevant circumstances, in which in addition to basic business conditions and basic drug conditions, including companies Financial information such as financial statements, books and books, various certificates, notes, and contracts must be submitted to the investigation team during 2010-2012. The list of listed companies including Yuheng Pharmaceutical, Hengrui Pharmaceutical, Hisun Pharmaceutical, Southwest Pharmaceutical, and Cologne Pharmaceuticals are all included in this cost survey list.

The reporter learned that since the beginning of this year, the NDRC has been mapping out the cost of medicines for pharmaceutical companies. It has conducted several rounds of research to prepare for the next price adjustment. According to the deployment, new drugs including the new base drug catalog, local supplementation of key base drugs and proprietary Chinese medicines will all be the focus of this year's price adjustment.

According to industry insiders, the current NDRC's specific content on the drug price survey is becoming more and more detailed, and the latest round of investigations has required companies to conduct field research on various types of bills. According to reports, the companies that have been included in the shortlisted companies include large-scale foreign companies in addition to listed companies. Most of them have new versions of the base drug short-listed products or even exclusive varieties, and related products may face price adjustments in the future.